DYN Dyne Therapeutics, Inc. Insider Trading

Director Jason P Rhodes sold 777,451 shares of Dyne Therapeutics (DYN) for $17.9M via scheduled 10b5-1 plan on 2026-07-06/07

Director Jason P Rhodes liquidated 99.6% of his holdings at Dyne Therapeutics through 10 separate sales totaling 777,451 shares for $17,858,491.67, leaving only 2,962 shares post-transaction. This was executed as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-19, meaning the sales were scheduled rather than discretionary. The company is unprofitable with net income of $-120,854,000.00 over its most recent full fiscal year. The blended average sale price of $22.97 compares favorably to the current price of $23.83, though the stock has appreciated 41.8% over the prior 30 days and remains 4.7% below its 52-week high of $25.00. The near-complete divestment of a director's position warrants investor attention given the company's unprofitable state, though the execution through a pre-arranged plan rather than discretionary trading limits inference about timing motivation.

Director Jason P Rhodes sells 504,695 shares ($10.7M) at DYN via 10b5-1 plan; stock up 14.9% in 30d.

Jason P Rhodes (Director) executed six separate sales totaling 504,695 shares for $10,712,549.82 at a blended average price of $21.23 between June 26 and June 29, 2026. This represents a 34.1% reduction in his holdings, from 1,480,626 to 975,931 shares. The sales were executed under a pre-arranged 10b5-1 trading plan adopted on 2026-03-19, meaning the trades were scheduled rather than discretionary. The company reported a net loss of $120,854,000 over its most recent full fiscal year, indicating unprofitability. Current stock price of $22.21 stands 11.2% below the 52-week high of $25.00, though the stock has appreciated 14.9% over the prior 30 days and 22.7% over the prior 90 days. His prior sales at DYN showed a median 30-day return of -6.3% (most recent batch on 2026-05-06), though 90-day outcomes for those trades remain not yet measurable. The scheduled nature of these sales under a Rule 10b5-1 plan precludes attribution to timing discretion.

DYN director Rhodes executes 9 sales totaling 267,760 shares for $5,646,496.80 under pre-arranged 10b5-1 plan

Jason P Rhodes sold 267,760 shares (267.8K shares) across 9 separate transactions on 2026-06-23 through 2026-06-25 for $5,646,496.80, reducing his holdings from 1,348,804 shares (1.35M shares) to 1,081,044 shares (1.08M shares)—a reduction of -19.9%. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-19, meaning execution is scheduled rather than discretionary. Dyne Therapeutics remains unprofitable with net income of $-120,854,000.00 ($-120.9M) over its most recent full fiscal year. The stock currently trades at $20.61, down -17.6% from its 52-week high of $25.00, though it has risen +13.6% over the past 30 days and +20.2% over 90 days. Rhodes' prior sales at DYN on 2026-05-06 showed a 30-day return of -6.3%, while his cross-ticker track record across 20 prior sells shows an average 30-day return of -1.1%, though outcomes at this specific ticker are limited for measuring predictive value.

Director Dirk Kersten sold 263,962 shares in 3 transactions for $5,464,611.43 via pre-arranged 10b5-1 plan

Dirk Kersten executed 3 separate sales totaling 263,962 shares ($5.5M) on June 22–23, 2026 at an average blended price of $20.70, reducing his holdings by 6.4%. The sales occurred via a pre-arranged 10b5-1 trading plan, making them scheduled rather than discretionary transactions. At the current price of $20.33, the stock trades -18.7% from its 52-week high of $25.00, though it has risen +17.0% over the past 30 days. Notably, Kersten's cross-ticker track record shows an average 90-day return of -39.7% following his prior 20 sells across all tickers, while his 5 prior trades at DYN alone show consistent 30-day declines ranging from -12.5% to -18.1%. Against this backdrop of consistent post-sale price deterioration, the company remains unprofitable with a net income of $-120,854,000.00 for its most recent fiscal year, adding context to the directional pressure on the stock following insider sales.

Dirk Kersten (Director) sold 84,355 shares at DYN for $1,695,689.49 under 10b5-1 plan; stock up 20.2% in 30 days.

Director Dirk Kersten executed 2 separate sales totaling 84,355 shares for $1,695,689.49 at a blended average price of $20.10, reducing his holding from 4,196,573 shares to 4,112,218 shares (a -2.0% net change). The sales were executed under a 10b5-1 trading plan, meaning they are scheduled and not discretionary. Notably, Kersten's cross-ticker track record shows 20 prior sells with an average 90-day return of -39.7%, while his same-ticker history at DYN (5 prior trades) shows consistent negative 30-day returns ranging from -12.5% to -18.1%. The company reported net income of $-120,854,000.00 for its most recent full fiscal year, reflecting unprofitable operations despite the current market cap of $2,980,751,217.69. Current price is $20.87, positioned at -16.5% from the 52-week high of $25.00.

Director Brian S Posner buys 2,000 shares of DYN at $16.94; cross-ticker avg 90d return +72.2%, but DYN fundamentals show $-120.9M net loss

Brian S Posner (Director) purchased 2,000 shares at $16.94 on 2026-06-08, bringing his non-derivative holdings to 24,500 shares, a net addition of 8.9% to pre-transaction holdings. His cross-ticker track record shows 6 prior open-market buys with an average 90-day return of +72.2% and a 90-day win rate of 83.33%, establishing a strong pattern of well-timed purchases across multiple securities. At DYN specifically, his 5 prior trades show 4 of 5 well-timed at the 90-day mark, though recent outcomes have been modest: the most recent buy on 2026-05-26 returned +1.1% over 90 days, while the May 20 purchase returned +7.5% over 90 days. The company remains fundamentally unprofitable with a net loss of $-120.9M for its most recent full fiscal year, creating tension between the insider's historical acumen in equity selection and the underlying financial distress of the target. The insider retains 35,152 shares of derivative holdings (stock options) after this transaction, indicating an ongoing exposure to DYN beyond the current purchase.

Director Posner buys 2.5K DYN shares at $17.48; holdings rise to 22.5K. 4 of 5 prior same-ticker buys well-timed; 90d win rate 83.33% cross-ticker.

Brian S Posner purchased 2,500 shares at $17.48 on 2026-06-03, growing his position to 22.5K shares (+12.5% from prior holdings). The stock has fallen -31.8% from its 52-week high of $25.00 and is currently at $17.04, down -9.6% over 30 days. Across his cross-ticker open-market history, Posner's 6 prior buys averaged +76.7% return in 30 days and +72.2% in 90 days, with an 83.33% win rate at 90 days. At DYN specifically, he has demonstrated a consistent pattern: 4 of his 5 prior trades at this ticker proved well-timed at the 90-day mark, including his most recent buy on 2026-05-26 (which posted +1.1% in 30 and 90 days). The company reported net income of $-120.9M over its most recent full fiscal year, underscoring the unprofitable status of the underlying business. This buy adds signal weight given his prior success at this specific ticker, though the company's negative profitability and the recent 30-day decline warrant evaluation of whether the market repricing reflects material changes.

Director Brian S Posner bought 2,000 shares of Dyne Therapeutics (DYN) at $18.21 on 2026-05-26, raising holdings to 20,000 shares despite -$120.9M net income.

Brian S Posner, Director of unprofitable Dyne Therapeutics (net income: -$120,854,000.00), purchased 2,000 shares at $18.21, expanding his stake by 11.1% to 20,000 shares. His cross-ticker track record shows strong execution: 4 prior open-market buys averaged +112.9% 30-day return and +101.6% 90-day return with a 75.00% 90-day win rate. At DYN specifically, however, his timing pattern is mixed: 2 of his 3 prior DYN purchases delivered positive 90-day returns, but the most recent buy on 2026-03-30 returned only +1.9% over 30 days, and his March 11 purchase lost -10.2% over 90 days. The current stock price of $18.56 sits -25.8% from its 52-week high of $25.00 but has recovered +18.8% over the past 90 days, suggesting some stabilization after earlier declines. This purchase signals director confidence in the near-term trajectory, though the company's continued unprofitability and mixed recent timing outcomes at this ticker warrant attention.

Director Brian S Posner buys 2,500 DYN shares at $17.12; 2 of 3 prior DYN buys showed positive 90-day returns.

Director Brian S Posner purchased 2,500 shares at $17.12 on 2026-05-20, increasing his holdings to 18,000 shares (+16.1% net change). His prior transaction history at Dyne Therapeutics shows mixed results: 2 of his 3 prior DYN buys generated positive 90-day returns (+1.7% and +15.3%), though one underperformed (-10.2%). His cross-ticker track record demonstrates stronger timing with 75.00% win rate and avg 90d return +101.6%, but this current purchase arrives as the stock trades at -30.5% from its 52-week high and -11.7% over the past 30 days. The company remains unprofitable with net income of $-120.9M over its most recent fiscal year, which limits visibility into whether this buy reflects conviction in a recovery or operational turnaround.

Director Rhodes unloads ~$1.9M in DYN shares; stock well below 52-week high amid persistent insider-selling pattern and unprofitable fundamentals.

Jason P. Rhodes, a director of Dyne Therapeutics, disposed of over 106,000 shares across three trading days in early May for approximately $1.9 million total. The stock is currently trading well below its 52-week high, having declined significantly from recent peaks. This sale adds to Rhodes' long-standing pattern of open-market dispositions—he has now executed 83 open-market sales over the past 36 months, with all five of his prior sales at this specific ticker proving poorly-timed, as the stock rose following each exit. Notably, the company is unprofitable with significant annual losses, and Rhodes' sustained selling activity over an extended period suggests a consistent orientation toward reducing exposure rather than conviction about near-term upside. The combination of persistent board-level sales, weak fundamentals, and the director's poor historical timing on prior DYN exits warrants closer scrutiny of whether operational challenges are driving these dispositions.